查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1887196

凝血因子市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032）

Coagulation Factors Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

凝血因子市場成長驅動因子

全球凝血因子市場正經歷顯著成長，主要受血友病A、血友病B和血管性血友病等出血性疾病先進療法需求不斷增長的推動。根據最新的產業分析，2024年全球市場規模為64億美元，2025年將增至68.9億美元，預計到2032年將達到121.9億美元，這主要得益於技術創新、血漿採集能力的提升以及人們對遺傳性出血性疾病認識的不斷提高。 2024年，北美以58.44%的市佔率領跑，這得益於其強大的醫療保健基礎設施和血漿衍生療法的日益普及。

凝血因子在維持正常血液凝固過程中扮演至關重要的角色。隨著全球出血性疾病和創傷病例的不斷增加，對血漿衍生和重組凝血產品的需求持續增長。包括CSL、Octapharma AG、Kedrion S.p.A.和武田藥品工業株式會社在內的主要行業領導者正在加強研發管線並擴大生產能力，以滿足全球治療需求。

市場驅動因素

推動市場成長的關鍵因素是全球遺傳性出血性疾病發生率的上升。根據美國疾病管制與預防中心（CDC）統計，美國約有33,000名男性患有血友病，而血管性血友病影響約1%的美國人口。診斷率的提高、患者意識的增強以及醫療服務提供者對早期治療的日益重視，持續推動凝血療法的需求成長。

全球傷害和事故發生率的上升也顯著促進了市場擴張。光是在印度，預計2022年道路交通事故將達到461,312起，比前一年增長11.9%。急診和重症監護機構對凝血因子的大量使用進一步支撐了市場成長趨勢。

市場限制因子

儘管成長潛力巨大，但嚴格的監管框架對製造商構成了挑戰。血漿的採集和處理必須符合FDA等機構制定的嚴格安全和品質標準，這些機構根據 "公共衛生服務法" 和 "聯邦食品、藥品和化妝品法" 監管血漿療法。漫長的審批週期和嚴格的營運要求可能會延遲產品上市，並限制市場擴張，尤其是在新興經濟體。

高昂的生產成本也限制了新進入者，因為血漿分離和生產基礎設施需要大量的資本投資。發展中地區有限的保險覆蓋範圍進一步限制了患者獲得治療的機會。

市場機會

對先進療法的研發投入不斷增加，為市場參與者提供了巨大的機會。新的血漿分離設施、不斷擴大的治療適應症、標靶給藥系統和長效因子製劑正在塑造下一波創新浪潮。例如，CSL Behring 將於 2022 年在澳洲開設一家新的血漿分離工廠，以支持血友病和其他嚴重疾病的治療，這體現了該行業致力於擴大全球產能的決心。

人工智慧和物聯網的進步正在提高生產效率、供應鏈透明度和患者支援水平，從而加速下一代療法的應用。

細分市場分析

依類型

預計到 2024 年，VIII 因子細分市場將佔最大的市場佔有率，這主要得益於血友病 A 的高發病率，據估計，全球有超過 110 萬人患有此病。纖維蛋白原濃縮物市場位居第二，這主要得益於監管部門的批准，例如 Octapharma 的 Fibryga 於 2024 年獲得美國 FDA 批准。

依應用領域劃分

血液學領域在 2024 年引領市場。這主要歸功於止血技術的進步以及先天性出血性疾病在全球範圍內的高發生率。血友病的盛行率估計為每 6,000 至 10,000 名男性中就有 1 例，這表明存在巨大的臨床需求。

依最終使用者劃分

2024 年，由於患者對專科護理的偏好、住院率的增加以及行業與醫療機構的合作，醫院和診所佔了大部分市場佔有率。由於對血漿衍生研發應用的需求不斷增長，臨床實驗室預計將保持穩定成長。

區域展望

北美

北美在2024年以37.4億美元的市場規模領先全球市場，這得益於其強大的血漿採集網絡、不斷增長的產品審批以及先進療法的廣泛應用。美國的血漿庫容量持續擴大，武田製藥旗下的BioLife Plasma Services於2023年開設了其第200家捐血中心。

歐洲

歐洲佔第二大市場佔有率，這得益於不斷擴大的血漿分離設施和強有力的監管支持。 CSL於2023年擴建其位於德國的血漿工廠，增強了該地區的供應能力。

亞太地區

由於併購活動增加、設施擴建以及血漿衍生產品價格的日益親民，預計該地區將實現強勁增長。 PlasmaGen Biosciences 等公司正在擴大生產規模，以滿足區域需求。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 出血性疾病的流行病學
  • 主要公司新產品發布
  • 主要產業趨勢，包括併購和合作
  • 關稅對市場的影響

第五章：全球凝血因子市場分析、洞察與預測 （2019-2032）

  • 依類型劃分的市場分析、洞察與預測
    • 凝血因子IX
    • 凝血因子VIII
    • 凝血酶原複合物濃縮物
    • 纖維蛋白原濃縮物
    • 其他
  • 依應用劃分的市場分析、洞察與預測
    • 免疫學和神經病學
    • 血液學
    • 重症監護
    • 其他
  • 依最終用戶劃分的市場分析、洞察和預測
    • 醫院和診所
    • 臨床研究實驗室
    • 其他
  • 依地區劃分的市場分析、洞察與預測
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲美洲
    • 中東和非洲

第六章 北美凝血因子市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲凝血因子市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區凝血因子市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲凝血因子市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲凝血因子市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會
    • 南非
    • 中東其他地區非洲

第十一章 競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
  • CSL
  • 武田藥品工業株式會社
  • 凱德瑞恩股份公司
  • 奧克塔製藥股份公司
  • LFB
  • 拜耳股份公司
Product Code: FBI112621

Growth Factors of coagulation factors Market

The global coagulation factors market is experiencing strong growth as demand rises for advanced therapies that treat bleeding disorders such as hemophilia A, hemophilia B, and von Willebrand disease. According to the latest industry analysis, the global market was valued at USD 6.40 billion in 2024, is projected to increase to USD 6.89 billion in 2025, and is expected to reach USD 12.19 billion by 2032, driven by technological innovations, expanding plasma collection capacity, and increased awareness of hereditary bleeding disorders. In 2024, North America dominated the market with a 58.44% share, supported by strong healthcare infrastructure and rising adoption of plasma-derived therapies.

Coagulation factors play a crucial role in supporting normal blood clotting. With the rising prevalence of bleeding disorders and trauma cases globally, demand for plasma-derived and recombinant coagulation products continues to accelerate. Key industry leaders-such as CSL, Octapharma AG, Kedrion S.p.A., and Takeda Pharmaceuticals-are strengthening their research pipelines while expanding manufacturing capacity to meet global therapeutic needs.

Market Drivers

A primary driver of market expansion is the growing incidence of hereditary bleeding disorders worldwide. According to the CDC, approximately 33,000 males in the U.S. live with hemophilia, and von Willebrand disease affects nearly 1% of the U.S. population. Rising diagnostic rates, improved patient awareness, and increased clinician focus on early-stage treatment continue to boost demand for coagulation therapies.

Rising trauma and accident rates globally also contribute significantly to market expansion. In India alone, 461,312 road accidents occurred in 2022, representing an 11.9% increase over the previous year. Emergency and critical care facilities rely heavily on coagulation factors for immediate treatment, further supporting the market's upward momentum.

Market Restraints

Despite strong growth potential, stringent regulatory frameworks pose challenges for manufacturers. Plasma collection and processing must comply with rigorous safety and quality standards enforced by agencies such as the FDA, which monitors plasma therapies under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. Lengthy approval cycles and strict operational requirements can slow product launches and limit market expansion, especially in emerging economies.

High production costs also restrict new market entrants, as plasma fractionation and manufacturing infrastructure require significant capital investment. Limited reimbursement coverage in developing regions further restricts treatment accessibility.

Market Opportunities

Increasing investments in R&D for advanced therapies offer significant opportunities for market players. New plasma fractionation facilities, expanded treatment indications, targeted delivery systems, and long-acting factor products are shaping the next wave of innovation. For example, CSL Behring opened a new plasma fractionation facility in Australia in 2022 to support treatments for hemophilia and other critical disorders, illustrating the industry's commitment to expanding global capacity.

Advancements in AI and IoT are improving manufacturing efficiency, supply chain visibility, and patient support, accelerating the adoption of next-generation therapies.

Segment Analysis

By Type

The Factor VIII segment held the largest market share in 2024, supported by high hemophilia A prevalence-estimated at over 1.1 million cases globally. The fibrinogen concentrates segment ranked second, fueled by regulatory approvals such as Octapharma's 2024 U.S. FDA approval for Fibryga.

By Application

The hematology segment dominated in 2024, driven by advancements in hemostasis technologies and a high global burden of congenital bleeding disorders. Prevalence of hemophilia is estimated at 1 in 6,000 to 10,000 males, highlighting the large clinical need.

By End User

Hospitals & clinics held the majority share in 2024 due to high patient preference for specialized treatment, increasing hospital admissions, and industry collaboration with healthcare institutions. Clinical research laboratories are expected to grow steadily with rising demand for plasma-derived R&D applications.

Regional Outlook

North America

North America led the global market in 2024 with USD 3.74 billion, driven by strong plasma collection networks, growing product approvals, and high adoption of advanced therapies. The U.S. continues to expand plasma banking capacity, with Takeda's BioLife Plasma Services opening its 200th donation center in 2023.

Europe

Europe holds the second-largest share, supported by expanded plasma fractionation facilities and strong regulatory backing. CSL's 2023 plasma plant expansion in Germany strengthens regional supply capabilities.

Asia Pacific

The region is projected to witness strong growth due to rising mergers, facility expansions, and increasing affordability of plasma-based products. Companies such as PlasmaGen Biosciences are expanding manufacturing operations to meet regional demand.

Conclusion

With a strong rise from USD 6.40 billion in 2024 to USD 6.89 billion in 2025, and a projected USD 12.19 billion market size by 2032, the coagulation factors industry is poised for sustained long-term growth. Strategic investments, technological innovation, and expanding treatment needs will continue to shape the global market landscape.

Segmentation By Type

  • Factor IX
  • Factor VIII
  • Prothrombin Complex Concentrates
  • Fibrinogen Concentrates
  • Others

By Application

  • Immunology & Neurology
  • Hematology
  • Critical Care
  • Others

By End User

  • Hospitals & Clinics
  • Clinical Research Laboratories
  • Others

By Geography

  • North America (By Type, Application, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Application, End User, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Application, End User, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of the Asia Pacific
  • Latin America (By Type, Application, End User, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Application, End User, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology of Bleeding Disorders
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
  • 4.4. Impact of Tariff on the Market

5. Global Coagulation Factors Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Factor IX
    • 5.1.2. Factor VIII
    • 5.1.3. Prothrombin Complex Concentrates
    • 5.1.4. Fibrinogen Concentrates
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Immunology & Neurology
    • 5.2.2. Hematology
    • 5.2.3. Critical Care
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Clinical Research Laboratories
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Coagulation Factors Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Factor IX
    • 6.1.2. Factor VIII
    • 6.1.3. Prothrombin Complex Concentrates
    • 6.1.4. Fibrinogen Concentrates
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Immunology & Neurology
    • 6.2.2. Hematology
    • 6.2.3. Critical Care
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Clinical Research Laboratories
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Coagulation Factors Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Factor IX
    • 7.1.2. Factor VIII
    • 7.1.3. Prothrombin Complex Concentrates
    • 7.1.4. Fibrinogen Concentrates
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Immunology & Neurology
    • 7.2.2. Hematology
    • 7.2.3. Critical Care
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Clinical Research Laboratories
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Coagulation Factors Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Factor IX
    • 8.1.2. Factor VIII
    • 8.1.3. Prothrombin Complex Concentrates
    • 8.1.4. Fibrinogen Concentrates
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Immunology & Neurology
    • 8.2.2. Hematology
    • 8.2.3. Critical Care
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Clinical Research Laboratories
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Coagulation Factors Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Factor IX
    • 9.1.2. Factor VIII
    • 9.1.3. Prothrombin Complex Concentrates
    • 9.1.4. Fibrinogen Concentrates
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Immunology & Neurology
    • 9.2.2. Hematology
    • 9.2.3. Critical Care
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Clinical Research Laboratories
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Coagulation Factors Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Factor IX
    • 10.1.2. Factor VIII
    • 10.1.3. Prothrombin Complex Concentrates
    • 10.1.4. Fibrinogen Concentrates
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Immunology & Neurology
    • 10.2.2. Hematology
    • 10.2.3. Critical Care
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospitals & Clinics
    • 10.3.2. Clinical Research Laboratories
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. CSL
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Takeda Pharmaceutical Company Limited
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Kedrion S.p.A.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Octapharma AG
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. LFB
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Bayer AG
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Coagulation Factors Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 2: Global Coagulation Factors Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 3: Global Coagulation Factors Market Revenue (USD billion) Forecast, by End User, 2019-2032
  • Table 4: Global Coagulation Factors Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Coagulation Factors Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 6: North America Coagulation Factors Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 7: North America Coagulation Factors Market Revenue (USD billion) Forecast, by End User, 2019-2032
  • Table 8: North America Coagulation Factors Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe Coagulation Factors Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 10: Europe Coagulation Factors Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 11: Europe Coagulation Factors Market Revenue (USD billion) Forecast, by End User, 2019-2032
  • Table 12: Europe Coagulation Factors Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Coagulation Factors Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 14: Asia Pacific Coagulation Factors Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 15: Asia Pacific Coagulation Factors Market Revenue (USD billion) Forecast, by End User, 2019-2032
  • Table 16: Asia Pacific Coagulation Factors Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Latin America Coagulation Factors Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 18: Latin America Coagulation Factors Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 19: Latin America Coagulation Factors Market Revenue (USD billion) Forecast, by End User, 2019-2032
  • Table 20: Latin America Coagulation Factors Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Coagulation Factors Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 22: Middle East & Africa Coagulation Factors Market Revenue (USD billion) Forecast, by Application, 2019-2032
  • Table 23: Middle East & Africa Coagulation Factors Market Revenue (USD billion) Forecast, by End User, 2019-2032
  • Table 24: Middle East & Africa Coagulation Factors Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Coagulation Factors Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Coagulation Factors Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global Coagulation Factors Market Value Share (%), by Application, 2024 & 2032
  • Figure 4: Global Coagulation Factors Market Value Share (%), by End User, 2024 & 2032
  • Figure 5: Global Coagulation Factors Market Value (USD billion), by Region, 2024 & 2032
  • Figure 6: North America Coagulation Factors Market Value (USD billion), by Type, 2024 & 2032
  • Figure 7: North America Coagulation Factors Market Value Share (%), by Type, 2024
  • Figure 8: North America Coagulation Factors Market Value (USD billion), by Application, 2024 & 2032
  • Figure 9: North America Coagulation Factors Market Value Share (%), by Application, 2024
  • Figure 10: North America Coagulation Factors Market Value (USD billion), by End User, 2024 & 2032
  • Figure 11: North America Coagulation Factors Market Value Share (%), by End User, 2024
  • Figure 12: North America Coagulation Factors Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America Coagulation Factors Market Value Share (%), By Country, 2024
  • Figure 14: Europe Coagulation Factors Market Value (USD billion), by Type, 2024 & 2032
  • Figure 15: Europe Coagulation Factors Market Value Share (%), by Type, 2024
  • Figure 16: Europe Coagulation Factors Market Value (USD billion), by Application, 2024 & 2032
  • Figure 17: Europe Coagulation Factors Market Value Share (%), by Application, 2024
  • Figure 18: Europe Coagulation Factors Market Value (USD billion), by End User, 2024 & 2032
  • Figure 19: Europe Coagulation Factors Market Value Share (%), by End User, 2024
  • Figure 20: Europe Coagulation Factors Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Coagulation Factors Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Coagulation Factors Market Value (USD billion), by Type, 2024 & 2032
  • Figure 23: Asia Pacific Coagulation Factors Market Value Share (%), by Type, 2024
  • Figure 24: Asia Pacific Coagulation Factors Market Value (USD billion), by Application, 2024 & 2032
  • Figure 25: Asia Pacific Coagulation Factors Market Value Share (%), by Application, 2024
  • Figure 26: Asia Pacific Coagulation Factors Market Value (USD billion), by End User, 2024 & 2032
  • Figure 27: Asia Pacific Coagulation Factors Market Value Share (%), by End User, 2024
  • Figure 28: Asia Pacific Coagulation Factors Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Coagulation Factors Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Latin America Coagulation Factors Market Value (USD billion), by Type, 2024 & 2032
  • Figure 31: Latin America Coagulation Factors Market Value Share (%), by Type, 2024
  • Figure 32: Latin America Coagulation Factors Market Value (USD billion), by Application, 2024 & 2032
  • Figure 33: Latin America Coagulation Factors Market Value Share (%), by Application, 2024
  • Figure 34: Latin America Coagulation Factors Market Value (USD billion), by End User, 2024 & 2032
  • Figure 35: Latin America Coagulation Factors Market Value Share (%), by End User, 2024
  • Figure 36: Latin America Coagulation Factors Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Coagulation Factors Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Coagulation Factors Market Value (USD billion), by Type, 2024 & 2032
  • Figure 39: Middle East & Africa Coagulation Factors Market Value Share (%), by Type, 2024
  • Figure 40: Middle East & Africa Coagulation Factors Market Value (USD billion), by Application, 2024 & 2032
  • Figure 41: Middle East & Africa Coagulation Factors Market Value Share (%), by Application, 2024
  • Figure 42: Middle East & Africa Coagulation Factors Market Value (USD billion), by End User, 2024 & 2032
  • Figure 43: Middle East & Africa Coagulation Factors Market Value Share (%), by End User, 2024
  • Figure 44: Middle East & Africa Coagulation Factors Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Coagulation Factors Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 46: Global Coagulation Factors Market Share (%), By Company, 2024